The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new biotechnology methods instead to spur innovation in the pharmaceutical ...

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...

The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

The biotechnology industry has long been characterized by astronomical development costs and lengthy timelines that can stretch into decades. Traditional drug development programs routinely require ...

Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines. And ...

Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

This week on "The Readout LOUD," a conversation with biotech "godfather" Stelios Papadapolous live from #STATBreakthrough.

Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...